Should Pharma Companies Waive Their COVID-19 Vaccine Patents? A Legal and Ethical Appraisal

IF 1.3 Q1 LAW
Laws Pub Date : 2023-05-23 DOI:10.3390/laws12030047
T. Cowart, Tsuriel Rashi, G. L. Bock
{"title":"Should Pharma Companies Waive Their COVID-19 Vaccine Patents? A Legal and Ethical Appraisal","authors":"T. Cowart, Tsuriel Rashi, G. L. Bock","doi":"10.3390/laws12030047","DOIUrl":null,"url":null,"abstract":"Pharmaceutical companies, like many other types of companies, are incentivized to create, manufacture, and distribute new products, in part due to the legal protections of patent law. However, the tension between patent rights and the public good has been heightened as pharma companies developed new vaccines to combat the COVID-19 pandemic. Wealthy governments paid well for vaccines and received ample supplies, while low- and middle-income countries struggled to obtain access to any vaccines. Some countries called for pharmaceutical companies to waive their patent protections for vaccines in order to facilitate the worldwide manufacture and distribution of COVID-19 vaccines. This paper will examine the rationale of patent protection and patent waiver issues, then compare these concepts with ethical constructs and a Jewish perspective.","PeriodicalId":30534,"journal":{"name":"Laws","volume":" ","pages":""},"PeriodicalIF":1.3000,"publicationDate":"2023-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Laws","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/laws12030047","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"LAW","Score":null,"Total":0}
引用次数: 0

Abstract

Pharmaceutical companies, like many other types of companies, are incentivized to create, manufacture, and distribute new products, in part due to the legal protections of patent law. However, the tension between patent rights and the public good has been heightened as pharma companies developed new vaccines to combat the COVID-19 pandemic. Wealthy governments paid well for vaccines and received ample supplies, while low- and middle-income countries struggled to obtain access to any vaccines. Some countries called for pharmaceutical companies to waive their patent protections for vaccines in order to facilitate the worldwide manufacture and distribution of COVID-19 vaccines. This paper will examine the rationale of patent protection and patent waiver issues, then compare these concepts with ethical constructs and a Jewish perspective.
制药公司应该放弃新冠肺炎疫苗专利吗?法律与伦理评价
制药公司和许多其他类型的公司一样,被激励创造、制造和分销新产品,部分原因是专利法的法律保护。然而,随着制药公司开发新疫苗以抗击新冠肺炎疫情,专利权与公共产品之间的紧张关系加剧。富裕国家政府为疫苗支付了高昂的费用,并获得了充足的供应,而中低收入国家则难以获得任何疫苗。一些国家呼吁制药公司放弃对疫苗的专利保护,以促进新冠肺炎疫苗的全球生产和分销。本文将研究专利保护和专利豁免问题的基本原理,然后将这些概念与伦理结构和犹太视角进行比较。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Laws
Laws LAW-
CiteScore
2.00
自引率
16.70%
发文量
77
审稿时长
11 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信